Close Menu

Disease Areas

News and analysis on disease research and diagnostics.

Nuclei's technology, rooted in tissue imaging, will be used to search for biomarkers that predict patients' responses to one of Debiopharm's agents.

The agency approved the drug based on a study that showed an 88 percent response rate in young patients with ALK-positive anaplastic large cell lymphoma.

The precision oncology company plans to use the proceeds to advance drugs in its pipeline, improve its RADR platform, and acquire new therapeutic assets.

Drugmakers discussed advancing autologous CAR T-cell therapeutic programs, and several diagnostic firms detailed their efforts in precision oncology.